Alnuctamab Biosimilar – Anti-TNFRSF17;CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA1642; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Alnuctamab Biosimilar, also known as Anti-TNFRSF17,CD3E mAb, is a novel monoclonal antibody that has recently gained attention in the field of immunotherapy. This biosimilar is a promising therapeutic agent for the treatment of various diseases, as it targets two important receptors involved in immune response – TNFRSF17 and CD3E. In this article, we will discuss the structure, activity, and potential applications of Alnuctamab Biosimilar in detail.
Alnuctamab Biosimilar is a monoclonal antibody that is produced by recombinant DNA technology. It is a chimeric antibody, meaning it is composed of both human and murine components. The antibody is composed of two heavy chains and two light chains, each with a variable region that recognizes and binds to specific targets. The variable regions of Alnuctamab Biosimilar are designed to target TNFRSF17 and CD3E receptors, making it a highly specific and effective therapeutic agent.
Alnuctamab Biosimilar works by binding to the TNFRSF17 and CD3E receptors, which are found on the surface of immune cells. TNFRSF17, also known as BCMA, is a receptor that is involved in the survival and proliferation of B cells, while CD3E is a receptor found on T cells that plays a crucial role in the activation of these cells. By targeting these receptors, Alnuctamab Biosimilar can modulate the immune response and potentially treat various diseases.
Alnuctamab Biosimilar is being studied for its potential use in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. TNFRSF17 is highly expressed on the surface of myeloma cells, making it a promising therapeutic target. Studies have shown that Alnuctamab Biosimilar can effectively target and kill myeloma cells, making it a potential treatment option for this disease.
In addition to multiple myeloma, Alnuctamab Biosimilar is also being investigated for its potential use in other B cell malignancies, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. These diseases also express high levels of TNFRSF17, making Alnuctamab Biosimilar a promising therapeutic option.
Furthermore, Alnuctamab Biosimilar has shown potential in the treatment of autoimmune diseases. By targeting the CD3E receptor on T cells, this biosimilar can modulate the immune response and potentially treat diseases such as rheumatoid arthritis and psoriasis.
In addition to its potential therapeutic applications, Alnuctamab Biosimilar is also available in a research grade form. This allows for further studies and research to be conducted on this novel antibody. Research grade Alnuctamab Biosimilar can be used in various in vitro and in vivo experiments to further understand its mechanism of action and potential applications.
In conclusion, Alnuctamab Biosimilar is a promising monoclonal antibody that targets TNFRSF17 and CD3E receptors. Its unique structure and mechanism of action make it a potential treatment option for various diseases, including multiple myeloma, B cell malignancies, and autoimmune diseases. With ongoing research and development, this biosimilar has the potential to make a significant impact in the field of immunotherapy.
ProteoGenix catalogue number PX-TA1642. For research use only.
Target: Alnuctamab Biosimilar – Anti-TNFRSF17;CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Alnuctamab Biosimilar – Anti-TNFRSF17;CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
